Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability

International Journal of Neuropsychopharmacology

Volumn 16, Issue 4, 2013, Pages 745-754

  Vernaleken, Ingo ^a   Klomp, Majken ^a   Moeller, Olaf ^a   Raptis, Mardjan ^a   Nagels, Arne ^a   Rösch, Frank ^b   Schaefer, Wolfgang M ^a   Cumming, Paul ^c   Gründer, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F fallypride; ketamine; positron emission tomography; psychosis; thought disorder; vulnerability

Indexed keywords

DESMOTHOXY FALLYPRIDE F 18; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUORODEOXYGLUCOSE F 18; KETAMINE; PLACEBO; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; DRUG BRAIN LEVEL; ENVIRONMENTAL STRESS; HUMAN; INFERIOR TEMPORAL GYRUS; LANGUAGE DISABILITY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RADIOCHEMISTRY; SCHIZOPHRENIA; THALAMUS; THOUGHT AND LANGUAGE INDEX; THOUGHT DISORDER;

ADULT; BENZAMIDES; GENETICS, BEHAVIORAL; HUMANS; KETAMINE; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SINGLE-BLIND METHOD; UP-REGULATION; YOUNG ADULT;

EID: 84875694512     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000764     Document Type: Article

References (57)

1. Aalto S, Hirvonen J, Kajander J, Scheinin H, et al. (2002). Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berlin) 164, 401-406.
2. Adams B, Moghaddam B (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. Journal of Neuroscience 18, 5545-5554.
3. Anand A, Charney DS, Oren DA, Berman RM, et al. (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Archives of General Psychiatry 57, 270-276.
4. Arieti S (1955). Interpretation of Schizophrenia. New York: Basic Books.
5. Braskie MN, Landau SM, Wilcox CE, Taylor SD, et al. (2011). Correlations of striatal dopamine synthesis with default network deactivations during working memory in younger adults. Human Brain Mapping 32, 947-961.
6. Breier A, Adler CM, Weisenfeld N, Su TP, et al. (1998). Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29, 142-147.
7. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, et al. (2006). D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research 85, 232-244.
8. Cloninger CR (1994). Temperament and Character Inventory (TCI): A Guide to Its Development and Use. St. Louis, MO: Center for Psychobiology of Personality, Washington University.
9. Cropley VL, Innis RB, Nathan PJ, Brown AK, et al. (2008). Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse 62, 399-408.
10. Dalley JW, Fryer TD, Brichard L, Robinson ES, et al. (2007). Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 315, 1267-1270.
11. Deep P, Dagher A, Sadikot A, Gjedde A, et al. (1999). Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 34, 313-318.
12. Durstewitz D, Seamans JK, Sejnowski TJ (2000). Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. Journal of Neurophysiology 83, 1733-1750.
13. Gjedde A, Kumakura Y, Cumming P, Linnet J, et al. (2010). Inverted-U-shaped correlation between dopamine receptor availability in striatum and sensation seeking. Proceedings of the National Academy of Sciences USA 107, 3870-3875.
14. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, et al. (2006). Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biological Psychiatry 60, 621-629.
15. Gründer G, Fellows C, Janouschek H, Veselinovic T, et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. American Journal of Psychiatry 165, 988-995.
16. Gründer G, Siessmeier T, Piel M, Vernaleken I, et al. (2003). Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. Journal of Nuclear Medicine 44, 109-116.
17. 11C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. European Journal of Nuclear Medicine and Molecular Imaging 30, 141-148.
18. Javitt DC, Lindsley RW (2001). Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque. Psychopharmacology (Berlin) 156, 165-168.
19. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
20. Kapur S, Seeman P (2001). Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor. Biological Psychiatry 49, 954-957.
21. Kato K, Shishido T, Ono M, Shishido K, et al. (2000). Effects of phencyclidine on behavior and extracellular levels of dopamine and its metabolites in neonatal ventral hippocampal damaged rats. Psychopharmacology (Berlin) 150, 163-169.
22. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, et al. (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biological Psychiatry 48, 627-640.
23. Kegeles LS, Martinez D, Kochan LD, Hwang DR, et al. (2002). NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43, 19-29.
24. Kegeles LS, Slifstein M, Xu X, Urban N, et al. (2010). Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biological Psychiatry 68, 634-641.
25. Klostermann EC, Braskie MN, Landau SM, O'Neil JP, Jagust WJ (2012). Dopamine and frontostriatal networks in cognitive aging. Neurobiology of Aging 33, 623. e15-e24.
26. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, et al. (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berlin) 179, 303-309.
27. Krystal JH, D'Souza DC, Karper LP, Bennett A, et al. (1999). Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berlin) 145, 193-204.
28. Krystal JH, Karper LP, Seibyl JP, Freeman GK, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 51, 199-214.
29. Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, et al. (2007). Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. Journal of Neuroscience 27, 8080-8087.
30. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
31. Large CH (2007). Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? Journal of Psychopharmacology 21, 283-301.
32. Liddle PF, Ngan ET, Caissie SL, Anderson CM, et al. (2002). Thought and Language Index: an instrument for assessing thought and language in schizophrenia. British Journal of Psychiatry 181, 326-330.
33. Malhotra AK, Pinals DA, Adler CM, Elman I, et al. (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17, 141-150.
34. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, et al. (2002). Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience 5, 267-271.
35. Murray HA (1943). The Thematic Apperception Test Manual. Cambridge, MA: Harvard University Press.
36. Nader MA, Morgan D, Gage HD, Nader SH, et al. (2006). PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nature Neuroscience 9, 1050-1056.
37. Nagels A, Kirner-Veselinovic A, Krach S, Kircher T (2011). Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency. Neuroimage 54, 1307-1314.
38. Oye I, Paulsen O, Maurset A (1992). Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics 260, 1209-1213.
39. Perry W, Braff DL (1994). Information-processing deficits and thought disorder in schizophrenia. American Journal of Psychiatry 151, 363-367.
40. Pinborg LH, Videbaek C, Ziebell M, Mackeprang T, et al. (2007). [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region. Neuroimage 34, 1450-1453.
41. Rominger A, Wagner E, Mille E, Boning G, et al. (2010). Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse. Synapse 64, 313-322.
42. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology 74, 1-58.
43. Skinbjerg M, Liow JS, Seneca N, Hong J, et al. (2010). D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. NeuroImage 50, 1402-1407.
44. Slifstein M, Kegeles LS, Xu X, Thompson JL, et al. (2010). Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 64, 350-362.
45. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18, 18-25.
46. Storms LH, Broen Jr. WE (1969). A theory of schizophrenic behavioral disorganization. Archives of General Psychiatry 20, 129-144.
47. 11C]DOPA: PET studies in the conscious monkey brain. Synapse 57, 116-119.
48. Umbricht D, Schmid L, Koller R, Vollenweider FX, et al. (2000). Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Archives of General Psychiatry 57, 1139-1147.
49. 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol. Journal of Cerebral Blood Flow and Metabolism 30, 994-1007.
50. Vernaleken I, Buchholz HG, Kumakura Y, Siessmeier T, et al. (2007). 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation. Human Brain Mapping 28, 931-939.
51. Vernaleken I, Janouschek H, Raptis M, Hellmann S, et al. (2010). Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. International Journal of Neuropsychopharmacology 13, 951-960.
52. Vernaleken I, Kumakura Y, Buchholz HG, Siessmeier T, et al. (2008). Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: a positron emission tomography study in healthy subjects. Neuroimage 40, 1222-1231.
53. Vernaleken I, Peters L, Raptis M, Lin R, et al. (2011). The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. Journal of Cerebral Blood Flow and Metabolism 31, 1958-1966.
54. Vernaleken I, Raptis M, Bartenstein P, Wong DF, et al. (2009) D2/3-Receptor availability in schizophrenia decreases with progression of psychosis. Journal of Nuclear Medicine 50 (Suppl. 2), 80.
55. Volkow ND, Gur RC, Wang GJ, Fowler JS, et al. (1998). Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. American Journal of Psychiatry 155, 344-349.
56. 11C]raclopride PET study of a model psychosis in humans. Journal of Psychiatric Research 34, 35-43.
57. Wong DF, Wagner Jr. HN, Tune LE, Dannals RF, et al. (1986). Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234, 1558-1563.